1-6 of 6
Thomas Habermann
Close
Sort by
Journal Articles

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Muhammad A. Mir, Matthew J. Maurer, Steven C. Ziesmer, Susan L. Slager, Thomas Habermann, William R. Macon, Brian K. Link, Sergei Syrbu, Thomas Witzig, Jonathan W. Friedberg, Oliver Press, Michael LeBlanc, James R. Cerhan, Anne Novak, Stephen M. Ansell
Journal: Blood
Blood (2015) 125 (6): 992–998.
https://doi.org/10.1182/blood-2014-06-583369
Published: 2015
Includes: Supplemental data
Journal Articles

A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma.

Grzegorz S. Nowakowski, Betsy LaPlant, Thomas Habermann, David J Inwards, Patrick L Johnston, MD, PhD, Clive S. Zent, MD, Craig B. Reeder, MD, Thomas E Witzig, MD
Journal: Blood
Blood (2009) 114 (22): 1669.
https://doi.org/10.1182/blood.V114.22.1669.1669
Published: 2009
Journal Articles

Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Julie M. Vose, M.D., Thomas Habermann, Myron S Czuczman, Pier Luigi Zinzani, Craig B. Reeder, MD, Joseph Tuscano, MD, Izidore S Lossos, MD, Dennis Pietronigro, Annette Ervin-Haynes, Thomas Witzig
Journal: Blood
Blood (2009) 114 (22): 2699.
https://doi.org/10.1182/blood.V114.22.2699.2699
Published: 2009
Journal Articles

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

Kerry J. Savage, Stefano Monti, Jeffery L. Kutok, Giorgio Cattoretti, Donna Neuberg, Laurence de Leval, Paul Kurtin, Paola Dal Cin, Christine Ladd, Friedrich Feuerhake, Ricardo C. T. Aguiar, Sigui Li, Gilles Salles, Francoise Berger, Wen Jing, Geraldine S. Pinkus, Thomas Habermann, Riccardo Dalla-Favera, Nancy Lee Harris, Jon C. Aster, Todd R. Golub, Margaret A. Shipp
Journal: Blood
Blood (2003) 102 (12): 3871–3879.
https://doi.org/10.1182/blood-2003-06-1841
Published: 2003
Includes: Supplemental data
Journal Articles

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Clinical Trials & Observations
Joseph A. Sparano, Edie Weller, Tipu Nazeer, Thomas Habermann, Ann E. Traynor, Jane Manalo, Peter Cassileth
Journal: Blood
Blood (2002) 100 (5): 1634–1640.
https://doi.org/10.1182/blood.V100.5.1634.h81702001634_1634_1640
Published: 2002
Journal Articles

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Clinical Trials & Observations
Ian W. Flinn, Kenneth J. Kopecky, M. Kathryn Foucar, David Head, John M. Bennett, Robert Hutchison, William Corbett, Peter Cassileth, Thomas Habermann, Harvey Golomb, Kanti Rai, Elizabeth Eisenhauer, Frederick Appelbaum, Bruce Cheson, Michael R. Grever
Journal: Blood
Blood (2000) 96 (9): 2981–2986.
https://doi.org/10.1182/blood.V96.9.2981
Published: 2000